Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
about
Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in AustraliaSystematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.Mechanistic mathematical models: An underused platform for HPV research.Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.Medical costs for the treatment of cervical cancer at central hospitals in Vietnam.What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vacciProtocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention.
P2860
Q36251151-AC1A1643-19D6-4F11-98DD-D17DE1EC8B6CQ36325832-86BCED38-1E4A-4C78-977F-7ACEDB6B63FAQ38673360-8C427C9A-9C24-4F8D-AAC9-3E1821837DC9Q47563209-99D930BC-B133-4853-923B-5905A3675EDFQ47583667-88DBBD9B-BA0F-46D5-94E0-B2F6174CAA64Q47653424-A5F52B60-1484-43AC-9F39-09CF13FED1B2Q47674683-3BAFC803-9AE4-4C66-8518-B1F437CB15ECQ49644195-8C4D948A-2CDA-4B57-ADB5-9FCFF0496E0AQ52585308-10C26217-72A3-41DD-8F3F-9E9F62F2DD08Q52727412-F1A7340F-BC8D-411E-93DC-72546F78D08EQ55385410-727C5E87-6274-4EF3-BF54-CDF4495AB879
P2860
Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Will cervical screening remain ...... for four developed countries.
@en
type
label
Will cervical screening remain ...... for four developed countries.
@en
prefLabel
Will cervical screening remain ...... for four developed countries.
@en
P2093
P2860
P50
P356
P1476
Will cervical screening remain ...... for four developed countries.
@en
P2093
Henry C Kitchener
Karen Canfell
Philip E Castle
P2860
P304
P356
10.1002/IJC.30392
P577
2016-08-19T00:00:00Z